Data from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
Meagan B. Ryan(Sage Therapeutics (United States)), Margit Hagel(Unknown), Klaus P. Hoeflich(Pivot), Ayşegül Özen(Sage Therapeutics (United States)), Steven E. Cohen(Sage Therapeutics (United States)), Arvin C. Dar(Memorial Sloan Kettering Cancer Center), Natasha Schenk(Novartis (United States)), Chun Li(Sage Therapeutics (United States)), Michael Hale(Sage Therapeutics (United States)), Brooke M. Swalm(Sage Therapeutics (United States)), Bradley Quade(Sage Therapeutics (United States)), Marshall Zingg(Sage Therapeutics (United States)), Yongxin Han(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xin Huang(Amgen (United States)), Maria Stella Ritorto(University of Dundee), Zhong Fang(Sage Therapeutics (United States)), Chaoyang Ye(Blueprint Medicines (United States))
Cited by 1
Related Papers
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
|Nature Medicine|2018|1k
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
|Annual Review of Biochemistry|2011|391